Clinical bottom line
High-flow nasal cannula (HFNC) oxygen therapy is an effective and well-tolerated modality for managing acute respiratory failure (ARF) in the emergency department (ED). Recent high-quality evidence indicates that HFNC is non-inferior to noninvasive ventilation (NIV) for many patients, with potential benefits including improved comfort, ease of use, and reduced need for escalation to invasive mechanical ventilation. However, patient selection remains critical, especially in hypercapnic respiratory failure, where NIV may still be preferred. Incorporation of HFNC into ED respiratory support algorithms can enhance early management of ARF while allowing close monitoring for treatment failure (RENOVATE Investigators et al., 2025; Goel et al., 2026).
What the evidence shows
The RENOVATE randomized clinical trial (2025) compared HFNC with NIV in patients with acute respiratory failure and found that HFNC was non-inferior regarding mortality and intubation rates. Patients receiving HFNC reported greater comfort and fewer adverse events, supporting its use as a first-line therapy in hypoxemic respiratory failure.
Goel et al. (2026) provide an official American Thoracic Society guideline endorsing HFNC as a valid option for ARF, emphasizing its role in hypoxemic patients and recommending NIV preferentially for hypercapnic respiratory failure.
Tan et al. (2024) conducted a randomized controlled non-inferiority trial comparing HFNC and NIV in acute exacerbations of COPD with moderate hypercapnia, finding HFNC non-inferior in preventing treatment failure, though NIV remains standard in severe cases.
Earlier systematic reviews (Algamdi et al., 2016) and observational studies (Haywood et al., 2020; Bottani et al., 2018) have consistently shown HFNC improves oxygenation, reduces work of breathing, and enhances patient tolerance compared to conventional oxygen therapy.
Long et al. (2018) demonstrated that HFNC reduces escalation to invasive ventilation compared to conventional oxygen in ARF, highlighting its utility in the ED setting.
Caveats and uncertainty
While HFNC is effective in hypoxemic respiratory failure, its role in hypercapnic respiratory failure is less clear and may be limited to mild-to-moderate cases.
Delayed recognition of HFNC failure can lead to worse outcomes; close monitoring and clear criteria for escalation are essential.
Heterogeneity in patient populations and ARF etiologies across studies may affect generalizability.
Resource availability, staff training, and device costs may impact implementation in some EDs.
Long-term outcomes beyond hospital discharge remain underreported.
How this may change practice
Emergency clinicians should consider HFNC as a frontline respiratory support option for patients presenting with hypoxemic ARF, balancing benefits of comfort and ease of use.
Protocols incorporating early HFNC initiation with vigilant monitoring for signs of deterioration can optimize patient outcomes.
In hypercapnic respiratory failure, NIV remains preferred, but HFNC may be an alternative in selected patients intolerant of NIV.
Education and training on HFNC indications, setup, and monitoring are critical for safe adoption.
Future guidelines will likely integrate HFNC more prominently as evidence accumulates.